grade
pharmaceutical primary standard
vapor density
3.5 (vs air)
API family
cyclizine
manufacturer/tradename
EDQM
bp
138 °C (lit.)
density
0.903 g/mL at 25 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
CN1CCNCC1
InChI
1S/C5H12N2/c1-7-4-2-6-3-5-7/h6H,2-5H2,1H3
InChI key
PVOAHINGSUIXLS-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Cyclizine impurity A EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Inhalation - Eye Dam. 1 - Flam. Liq. 3 - Skin Corr. 1B - Skin Sens. 1B
存储类别
3 - Flammable liquids
wgk
WGK 1
flash_point_f
88.7 °F - closed cup
flash_point_c
31.5 °C - closed cup
法规信息
危险化学品
此项目有
Almeqdad Y Habashneh et al.
Archiv der Pharmazie, 347(6), 415-422 (2014-03-13)
A new series of N1-(flavon-6-yl)amidrazones were synthesized by reacting the hydrazonoyl chloride derived from 6-aminoflavone with the appropriate sec-cyclic amines. The antitumor activities of these compounds were evaluated on breast cancer (MCF-7) and leukemic (K562) cell lines. Among the compounds
Jin-Ping Li et al.
Drug design, development and therapy, 9, 1027-1062 (2015-03-04)
Danusertib (Danu) is a pan-inhibitor of Aurora kinases and a third-generation breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (Bcr-Abl) tyrosine kinase inhibitor, but its antitumor effect and underlying mechanisms in the treatment of human breast cancer remain elusive.
Son T Nguyen et al.
Bioorganic & medicinal chemistry, 23(9), 2024-2034 (2015-03-31)
Recently we described a novel pyranopyridine inhibitor (MBX2319) of RND-type efflux pumps of the Enterobacteriaceae. MBX2319 (3,3-dimethyl-5-cyano-8-morpholino-6-(phenethylthio)-3,4-dihydro-1H-pyrano[3,4-c]pyridine) is structurally distinct from other known Gram-negative efflux pump inhibitors (EPIs), such as 1-(1-naphthylmethyl)-piperazine (NMP), phenylalanylarginine-β-naphthylamide (PAβN), D13-9001, and the pyridopyrimidine derivatives. Here
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| Y0000886 | 04061833805459 |